A Phase 4 interventional study of Insulin glargine and Inhaled Insulin (Exubera) in Diabetes Mellitus, Type 2, sponsored by Pfizer. Completed at 73 sites in 2 countries. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing insulin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 1 of them phase 3. Insulin · Diabetes Mellitus, Type 2.
Among the 54 studies testing insulin in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 2 that started in 2007, is one of 20 in phase 4, and was the 9th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing insulin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 55–80
Ohio State University · Sites in United States
Ages 18+ · Women only
Emory University · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 30 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 8 · Phase 4 20
First in 1995; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 413 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 60 across the 54 interventional studies. Of the 44 that completed or were terminated, 19 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
80 studies in Diabetes Mellitus, Type 2 by Pfizer: 2 open now, 3 under way, 3 of them phase 3. Of 77 finished, 39 (51%) have results posted.
Among the 80 studies in Diabetes Mellitus, Type 2 by Pfizer, this one is the 6th largest by enrollment of the 79 interventional ones that give a count, is one of 8 that started in 2007, is one of 4 in phase 4, and was the 9th registered.
Pfizer’s Diabetes Mellitus, Type 2 studies by the year they started, since 1999.
3 of the studies testing insulin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06251635Centre for Addiction and Mental HealthEffects of Antipsychotics on Brain Insulin Action in Females | 2026-12-31 |
| NCT06699810Emory UniversityModeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity | 2027-01 |
| NCT07293715Ohio State UniversityPermissive Versus Strict Intrapartum Glucose Management in Type 1 and Type 2 Diabetes (PRISM) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies testing insulin in Diabetes Mellitus, Type 2, from their registry updates:
Among Pfizer’s 80 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This study is to determine if inhaled insulin is effective in treating type 2 diabetes mellitus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Smoking within last 6 months PFTs outside of range
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
Drug: Insulin glargine
Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
Drug: Inhaled Insulin (Exubera)
Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population
HbA1c lab value: Change = value at Week 26 minus value at Baseline.
Time frame: Baseline, Week 26
Percentage of Subjects Achieving Glycemic Control (HbA1c < 6.5%) at Week 26
Percentage of subjects with glycosylated hemoglobin A1c lab value less than 6.5%.
Time frame: Week 26
Percentage of Subjects Achieving Glycemic Control (HbA1c < 7.0%) at Week 26
Percentage of subjects with glycosylated hemoglobin A1c lab value less than 7.0%.
Time frame: Week 26
Percentage of Subjects Achieving Glycemic Control (HbA1c < 8.0%) at Week 26
Number of subjects with glycosylated hemoglobin A1c lab value less than 8.0%.
Time frame: Week 26
Change From Baseline in Fasting Plasma Glucose at Week 26
Fasting plasma glucose lab value: Change = value at Week 26 minus value at Baseline.
Time frame: Baseline, Week 26
Change From Baseline in Fasting and Postprandial Blood Glucose as Determined by Standardized Meal Tolerance Tests at Week 26
Postprandial blood glucose lab value (Time 0 min \[fasting\], Time 30 min, Time 60 min, Time 90 min, Time 120 min, Time 180 min): Change = value at Week 26 minus value at Baseline.
Time frame: Baseline, Week 26
Change From Baseline in Postprandial Blood Glucose as Measured by 8-Point Profiles at Week 26
Post-prandial=after a meal. 8-point scale: (1 = before breakfast, 2 = 2 hours post breakfast, 3 = before lunch, 4 = 2 hours post lunch, 5 = before dinner, 6 = 2 hours post dinner, 7 = at bedtime, 8 = overnight \[between 2 and 4 am\]). Postprandial blood glucose lab value: Change = value at Week 26 minus value at Baseline.
Time frame: Baseline, Week 26
Change From Baseline in Lipids at Week 26
Lipid (total cholesterol, high density lipoprotein cholesterol \[HDL-c\], low density lipoprotein cholesterol \[LDL-c\], triglycerides) lab value: Change = value at Week 26 minus value at Baseline.
Time frame: Baseline, Week 26
Change From Baseline in Cardiovascular (CV) Biomarkers High Sensitivity C-reactive Protein (Hs-CRP), Leptin, and Spot Urine Microalbumin at Week 26
CV biomarker (hs-CRP, Leptin, and Spot Urine Microalbumin) lab value: Change = value at Week 26 minus value at Baseline.
Time frame: Baseline, Week 26
Change From Baseline in CV Biomarkers Adiponectin and Apolipoprotein B (ApoB) at Week 26
CV biomarker (adiponectin and ApoB) lab value: Change = value at Week 26 minus value at Baseline.
Time frame: Baseline, Week 26
Change From Baseline in 24-Hour Continuous Glucose Monitoring System (CGMS) Glucose Values at Week 26
24-Hour CGMS glucose lab value was obtained using the Medtronic MiniMed CGMS. Not all subjects were offered the opportunity to participate in this assessment. Change = value at Week 26 minus value at Baseline.
Time frame: Baseline, Week 26
Change From Baseline in Mean Standard Deviation (SD) of 24-Hour Glucose Values Measured by CGMS at Week 26
SD of 24-Hour CGMS glucose lab value obtained using the Medtronic MiniMed CGMS. Not all subjects were offered the opportunity to participate in this assessment. Change = value at Week 26 minus value at Baseline.
Time frame: Baseline, Week 26
Number of Subjects With Hypoglycemic Events
A hypoglycemic event was identified by characteristic symptoms or blood glucose levels. An event was severe if the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Overall=mild, moderate, and severe.
Time frame: Months 1 to 7
Number of Total Hypoglycemic Events
A hypoglycemic event was identified by characteristic symptoms or blood glucose levels. Severe=the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Overall=mild, moderate, and severe. Total=events during the study.
Time frame: Months 1 to 7
Number of Total Subject Months of Treatment
Number of total subject months of treatment. Subject months = number of days from start of treatment to the last day of active treatment + 1 day lag, including off-drug time)/30.44. Severe=the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Overall=mild, moderate, and severe.
Time frame: Months 1 to 7
Crude Hypoglycemic Event Rate
crude event rate=(events)/(subject-months). Severe=the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Overall=mild, moderate, and severe.
Time frame: Months 1 to 7
Number of Nocturnal Hypoglycemic Events
A hypoglycemic event was identified by characteristic symptoms or blood glucose levels. Severe=the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Nocturnal hypoglycemia=event occuring from midnight to 5:59 am.
Time frame: Months 1 to 7
Change From Baseline in Body Weight at Week 26
Body weight value: Change = value at Week 26 minus value at Baseline.
Time frame: Baseline, Week 26
Change From Baseline in Body Mass Index (BMI) at Week 26
BMI value (kg/m2): Change = value at Week 26 minus value at Baseline.
Time frame: Baseline, Week 26
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the FAS
HbA1c lab value: Change = value at Week 26 minus value at Baseline.
Time frame: Baseline, Week 26
| Milestone | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Started | 219 | 194 |
| Received treatment | 212 | 190 |
| Completed | 136 | 152 |
| Not completed | 83 | 42 |
| Withdrew: Adverse event | 7 | 1 |
| Withdrew: Lack of efficacy | 1 | 3 |
| Withdrew: Lost to follow-up | 10 | 4 |
| Withdrew: Withdrawal by subject | 31 | 7 |
| Withdrew: Other | 27 | 23 |
| Withdrew: Randomized but did not receive treatment | 7 | 4 |
HbA1c lab value: Change = value at Week 26 minus value at Baseline.
| percent | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population | -2.01 ± 1.39 | -1.75 ± 1.40 |
Percentage of subjects with glycosylated hemoglobin A1c lab value less than 6.5%.
| percentage of participants | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Percentage of Subjects Achieving Glycemic Control (HbA1c < 6.5%) at Week 26 | 35.5 | 22.2 |
Percentage of subjects with glycosylated hemoglobin A1c lab value less than 7.0%.
| percentage of participants | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Percentage of Subjects Achieving Glycemic Control (HbA1c < 7.0%) at Week 26 | 62.6 | 47.6 |
Number of subjects with glycosylated hemoglobin A1c lab value less than 8.0%.
| percentage of participants | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Percentage of Subjects Achieving Glycemic Control (HbA1c < 8.0%) at Week 26 | 79.8 | 83.6 |
Fasting plasma glucose lab value: Change = value at Week 26 minus value at Baseline.
| mg/dL | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 26 | -52.77 ± 69.48 | -53.50 ± 62.92 |
Postprandial blood glucose lab value (Time 0 min \[fasting\], Time 30 min, Time 60 min, Time 90 min, Time 120 min, Time 180 min): Change = value at Week 26 minus value at Baseline.
| mg/dL | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Time 0 at Week 26 | -35.22 ± 51.12 | -61.16 ± 54.68 |
| Time 30 at Week 26 | -49.91 ± 62.41 | -66.02 ± 62.32 |
| Time 60 at Week 26 | -56.83 ± 69.81 | -64.77 ± 64.47 |
| Time 90 at Week 26 | -64.94 ± 75.67 | -58.85 ± 64.58 |
| Time 120 at Week 26 | -66.59 ± 74.69 | -54.89 ± 63.02 |
| Time 180 at Week 26 | -66.99 ± 74.19 | -51.27 ± 59.92 |
Post-prandial=after a meal. 8-point scale: (1 = before breakfast, 2 = 2 hours post breakfast, 3 = before lunch, 4 = 2 hours post lunch, 5 = before dinner, 6 = 2 hours post dinner, 7 = at bedtime, 8 = overnight \[between 2 and 4 am\]). Postprandial blood glucose lab value: Change = value at Week 26 minus value at Baseline.
| mg/dL | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Post-Breakfast, Week 26 | -86.61 ± 85.98 | -75.36 ± 79.04 |
| Post-Lunch, Week 26 | -86.66 ± 77.49 | -58.51 ± 86.93 |
| Post-Dinner, Week 26 | -81.86 ± 75.94 | -59.20 ± 86.21 |
Lipid (total cholesterol, high density lipoprotein cholesterol \[HDL-c\], low density lipoprotein cholesterol \[LDL-c\], triglycerides) lab value: Change = value at Week 26 minus value at Baseline.
| mg/dL | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Total cholesterol, Week 26 | -2.80 ± 31.97 | -6.19 ± 29.95 |
| HDL-c, Week 26 | 2.97 ± 6.99 | 0.69 ± 6.07 |
| LDL-c, Week 26 | -2.09 ± 25.74 | -3.71 ± 23.63 |
| Triglycerides, Week 26 | -42.65 ± 87.70 | -46.23 ± 147.8 |
CV biomarker (hs-CRP, Leptin, and Spot Urine Microalbumin) lab value: Change = value at Week 26 minus value at Baseline.
| mg/L | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| hs-CRP, Week 26 | 0.61 ± 4.56 | 0.32 ± 3.69 |
| Leptin, Week 26 | 3.68 ± 13.50 | 4.41 ± 10.50 |
| Spot Urine Microalbumin, Week 26 | 3.47 ± 96.48 | 3.70 ± 54.53 |
CV biomarker (adiponectin and ApoB) lab value: Change = value at Week 26 minus value at Baseline.
| mg/mL | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Adiponectin, Week 26 | 0.23 ± 5.58 | -0.32 ± 5.15 |
| ApoB, Week 26 | -0.06 ± 0.19 | -0.06 ± 0.17 |
24-Hour CGMS glucose lab value was obtained using the Medtronic MiniMed CGMS. Not all subjects were offered the opportunity to participate in this assessment. Change = value at Week 26 minus value at Baseline.
| mg/dL | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Change From Baseline in 24-Hour Continuous Glucose Monitoring System (CGMS) Glucose Values at Week 26 | -36.53 ± 33.96 | -35.63 ± 58.19 |
SD of 24-Hour CGMS glucose lab value obtained using the Medtronic MiniMed CGMS. Not all subjects were offered the opportunity to participate in this assessment. Change = value at Week 26 minus value at Baseline.
| mg/dL | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Change From Baseline in Mean Standard Deviation (SD) of 24-Hour Glucose Values Measured by CGMS at Week 26 | -12.50 ± 2.55 | 4.46 ± 11.51 |
A hypoglycemic event was identified by characteristic symptoms or blood glucose levels. An event was severe if the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Overall=mild, moderate, and severe.
| participants | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Overall at Month 1 | 70 | 24 |
| Mild/Moderate at Month 1 | 69 | 24 |
| Severe at Month 1 | 0 | 0 |
| Overall at Month 2 | 98 | 38 |
| Mild/Moderate at Month 2 | 98 | 38 |
| Severe at Month 2 | 1 | 0 |
| Overall at Month 3 | 84 | 35 |
| Mild/Moderate at Month 3 | 83 | 35 |
| Severe at Month 3 | 3 | 0 |
| Overall at Month 4 | 61 | 25 |
| Mild/Moderate at Month 4 | 61 | 25 |
| Severe at Month 4 | 0 | 0 |
| Overall at Month 5 | 55 | 30 |
| Mild/Moderate at Month 5 | 55 | 30 |
| Severe at Month 5 | 0 | 0 |
| Overall at Month 6 | 42 | 31 |
| Mild/Moderate at Month 6 | 42 | 31 |
| Severe at Month 6 | 0 | 0 |
| Overall at Month 7 | 8 | 4 |
| Mild/Moderate at Month 7 | 8 | 4 |
| Severe at Month 7 | 0 | 0 |
A hypoglycemic event was identified by characteristic symptoms or blood glucose levels. Severe=the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Overall=mild, moderate, and severe. Total=events during the study.
| events | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Overall at Month 1 | 195 | 41 |
| Mild/Moderate at Month 1 | 194 | 41 |
| Severe at Month 1 | 0 | 0 |
| Overall at Month 2 | 365 | 66 |
| Mild/Moderate at Month 2 | 364 | 66 |
| Severe at Month 2 | 1 | 0 |
| Overall at Month 3 | 292 | 84 |
| Mild/Moderate at Month 3 | 289 | 84 |
| Severe at Month 3 | 3 | 0 |
| Overall at Month 4 | 166 | 51 |
| Mild/Moderate at Month 4 | 166 | 51 |
| Severe at Month 4 | 0 | 0 |
| Overall at Month 5 | 157 | 64 |
| Mild/Moderate at Month 5 | 157 | 64 |
| Severe at Month 5 | 0 | 0 |
| Overall at Month 6 | 119 | 63 |
| Mild/Moderate at Month 6 | 119 | 63 |
| Severe at Month 6 | 0 | 0 |
| Overall at Month 7 | 12 | 5 |
| Mild/Moderate at Month 7 | 12 | 5 |
| Severe at Month 7 | 0 | 0 |
Number of total subject months of treatment. Subject months = number of days from start of treatment to the last day of active treatment + 1 day lag, including off-drug time)/30.44. Severe=the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Overall=mild, moderate, and severe.
| subject months | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Overall at Month 1 | 145.8 | 82.4 |
| Mild/Moderate at Month 1 | 145.8 | 82.4 |
| Severe at Month 1 | 145.8 | 82.4 |
| Overall at Month 2 | 138.3 | 81.0 |
| Mild/Moderate at Month 2 | 138.3 | 81.0 |
| Severe at Month 2 | 138.3 | 81.0 |
| Overall at Month 3 | 128.8 | 80.4 |
| Mild/Moderate at Month 3 | 128.8 | 80.4 |
| Severe at Month 3 | 128.8 | 80.4 |
| Overall at Month 4 | 117.7 | 79.7 |
| Mild/Moderate at Month 4 | 117.7 | 79.7 |
| Severe at Month 4 | 117.7 | 79.7 |
| Overall at Month 5 | 112.2 | 77.9 |
| Mild/Moderate at Month 5 | 112.2 | 77.9 |
| Severe at Month 5 | 112.2 | 77.9 |
| Overall at Month 6 | 103.5 | 75.7 |
| Mild/Moderate at Month 6 | 103.5 | 75.7 |
| Severe at Month 6 | 103.5 | 75.7 |
| Overall at Month 7 | 12.8 | 6.6 |
| Mild/Moderate at Month 7 | 12.8 | 6.6 |
| Severe at Month 7 | 12.8 | 6.6 |
crude event rate=(events)/(subject-months). Severe=the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Overall=mild, moderate, and severe.
| events / subject-months | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Overall at Month 1 | 1.3 | 0.5 |
| Mild/Moderate at Month 1 | 1.3 | 0.5 |
| Severe at Month 1 | 0 | 0 |
| Overall at Month 2 | 2.6 | 0.8 |
| Mild/Moderate at Month 2 | 2.6 | 0.8 |
| Severe at Month 2 | 0.7 | 0 |
| Overall at Month 3 | 2.3 | 1.0 |
| Mild/Moderate at Month 3 | 2.2 | 1.0 |
| Severe at Month 3 | 2.3 | 0 |
| Overall at Month 4 | 1.4 | 0.6 |
| Mild/Moderate at Month 4 | 1.4 | 0.6 |
| Severe at Month 4 | 0 | 0 |
| Overall at Month 5 | 1.4 | 0.8 |
| Mild/Moderate at Month 5 | 1.4 | 0.8 |
| Severe at Month 5 | 0 | 0 |
| Overall at Month 6 | 1.2 | 0.8 |
| Mild/Moderate at Month 6 | 1.2 | 0.8 |
| Severe at Month 6 | 0 | 0 |
| Overall at Month 7 | 0.9 | 0.8 |
| Mild/Moderate at Month 7 | 0.9 | 0.8 |
| Severe at Month 7 | 0 | 0 |
A hypoglycemic event was identified by characteristic symptoms or blood glucose levels. Severe=the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Nocturnal hypoglycemia=event occuring from midnight to 5:59 am.
| events | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Number of Nocturnal Hypoglycemic Events | 187 | 114 |
Body weight value: Change = value at Week 26 minus value at Baseline.
| kg | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Change From Baseline in Body Weight at Week 26 | 3.55 ± 4.74 | 2.33 ± 3.80 |
BMI value (kg/m2): Change = value at Week 26 minus value at Baseline.
| kg/m2 | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Change From Baseline in Body Mass Index (BMI) at Week 26 | 1.22 ± 1.66 | 0.80 ± 1.30 |
HbA1c lab value: Change = value at Week 26 minus value at Baseline.
| percent | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the FAS | -1.91 ± 1.41 | -1.67 ± 1.38 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inhaled Human Insulin | — | — | — |
| Insulin Glargine | — | — | — |
| Event | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| PancreatitisGastrointestinal disorders | 2/212 | 0/190 |
| Angina pectorisCardiac disorders | 1/212 | 1/190 |
| Cardiovascular disorderCardiac disorders | 0/212 | 1/190 |
| SepsisInfections and infestations | 0/212 | 1/190 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/212 | 1/190 |
| Angina unstableCardiac disorders | 1/212 | 0/190 |
| PalpitationsCardiac disorders | 1/212 | 0/190 |
| Chest painGeneral disorders | 1/212 | 0/190 |
| Hepatitis AInfections and infestations | 1/212 | 0/190 |
| Ankle fractureInjury, poisoning and procedural complications | 1/212 | 0/190 |
| Event | Inhaled Human Insulin | Insulin Glargine |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 144/212 | 83/190 |
| TremorNervous system disorders | 67/212 | 43/190 |
| DizzinessNervous system disorders | 40/212 | 29/190 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 35/212 | 21/190 |
| Upper respiratory tract infectionInfections and infestations | 23/212 | 29/190 |
| HeadacheNervous system disorders | 29/212 | 17/190 |
| AstheniaGeneral disorders | 28/212 | 17/190 |
| NauseaGastrointestinal disorders | 21/212 | 15/190 |
| CoughRespiratory, thoracic and mediastinal disorders | 18/212 | 6/190 |
| Weight increasedInvestigations | 17/212 | 9/190 |
| Age, Customized(participants) | Inhaled Human Insulin | Insulin Glargine | Total |
|---|---|---|---|
| 18 to 44 years | 27 | 26 | 53 |
| 45 to 65 years | 151 | 125 | 276 |
| >=65 years | 34 | 39 | 73 |
| Sex: Female, Male(Participants) | Inhaled Human Insulin | Insulin Glargine | Total |
|---|---|---|---|
| Female | 92 | 84 | 176 |
| Male | 120 | 106 | 226 |
| Gender(Participants) | Inhaled Human Insulin | Insulin Glargine | Total |
|---|---|---|---|
| Female | 92 | 84 | 176 |
| Male | 120 | 106 | 226 |
The record gives a start of Mar 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin